BioPorto

Description

BioPorto supplies in vitro diagnostic assays, antibodies, and ELISA kits that measure the NGAL biomarker to support earlier detection and risk assessment of acute kidney injury in clinical and research laboratory workflows.

BioPorto is located in the Copenhagen ecosystem.

Related

• CimCureCimCure develops conjugate cancer vaccines that induce antibody responses against tumour blood-vessel targets, applying its proprietary…
• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• 21st.BIO21st.BIO A/S provides precision fermentation technology for proteins and peptides, using microbial strains, fermentation processes, and…
• 3B Pharmaceuticals3B Pharmaceuticals develops targeted radiopharmaceuticals under a targeted radiotherapy program that builds peptide‑based theragnostic and…
• 3H Biomedical3H Biomedical supplies researchers with a broad catalog of primary human and animal cells, purified nucleic acids, cell culture media, and…
• AbbelightAbbelight provides integrated microscopy and nanoscopy instruments, reagents, and analysis software for quantitative bioimaging workflows,…
• Ability PharmaAbility Pharma develops oral targeted anticancer compounds that induce cytotoxic autophagy in cancer cells and advances clinical-stage…
• AACD PharmaACD Pharma develops bacteriophage-based biocontrol products and technologies for preventing and treating bacterial infections, with…
• AciesBioAciesBio provides microbial biotech services for strain engineering, scale-up process design, fermentation-broth processing, contract…